Fortress Biotech Inc. (FBIO)
NASDAQ: FBIO
· Real-Time Price · USD
1.85
0.10 (5.71%)
At close: May 02, 2025, 3:59 PM
1.77
-4.22%
After-hours: May 02, 2025, 04:13 PM EDT
5.71% (1D)
| Bid | 1.72 |
| Market Cap | 54.64M |
| Revenue (ttm) | 57.67M |
| Net Income (ttm) | -48.31M |
| EPS (ttm) | -2.69 |
| PE Ratio (ttm) | -0.69 |
| Forward PE | -4.18 |
| Analyst | Strong Buy |
| Ask | 1.82 |
| Volume | 202,230 |
| Avg. Volume (20D) | 280,512 |
| Open | 1.79 |
| Previous Close | 1.75 |
| Day's Range | 1.75 - 1.85 |
| 52-Week Range | 1.33 - 2.89 |
| Beta | 1.83 |
About FBIO
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 17, 2011
Employees 101
Stock Exchange NASDAQ
Ticker Symbol FBIO
Website https://www.fortressbiotech.com
Analyst Forecast
According to 3 analyst ratings, the average rating for FBIO stock is "Strong Buy." The 12-month stock price forecast is $21, which is an increase of 1036.36% from the latest price.
Stock Forecasts7 months ago
-18.48%
Fortress Biotech shares are trading lower after th...
Unlock content with
Pro Subscription
9 months ago
Fortress Biotech shares are trading lower after the company announced a pause in the payment of dividends on its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock.
